Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors - Seite 2
Noreen Griffin, CEO of Biostax, stated, “I warmly welcome Ms. Caperton to our esteemed Board of Directors. We are thrilled to have her on board, as her wealth of experience and unwavering dedication to excellence align perfectly with our company's vision and values. With her arrival, we anticipate not only the enhancement of our fundraising initiatives but also the fostering of valuable relationships with key organizations, paving the way for unprecedented growth and impact.”
Mrs. Caperton’s multifaceted career stands as a testament to her unwavering commitment to excellence, innovation, and impactful contributions to both the sports and not-for-profit sectors.
About Biostax
Biostax is an innovative biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology (MedTech) products with a well -defined path to market. We use
a hub-and-spoke business model, where the parent company (hub) holds a centralized management and administrative team, and each subsidiary (spoke) operates a specialized development team focused on
individual product pipelines.
Where Biostax has a diversity of product pipelines that will provide revenue while reducing risk, our goal is to develop new therapies that provide disease remission by restoring immune balance for
patients with autoimmune, inflammatory, and infectious diseases without suppressing their immune system. Restoring homeostasis or balance to the immune system is the first step to a cure by
improving patients’ lives in chronic illness caused by immune dysfunction and inflammation. www.biostaxcorp.com
Lesen Sie auch
Forward Looking Statement
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on
management’s beliefs, assumptions, and expectations of Immune’s future economic performance, considering the information currently available to it. These statements are not statements of historical
fact. Although Immune believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained.
Immune does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Immune will
successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause
Immune’s actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ
materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations,
regulatory review and approval of our prospective products, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities
and Exchange Commission.